Company profile: Appili Therapeutics
1.1 - Company Overview
Company description
- Provider of anti-infective pharmaceutical development solutions, addressing unmet medical needs with improvements to established therapies and new classes of anti-infectives. Pipeline includes ATI-1701, a live-attenuated tularemia vaccine candidate; ATI-1801, a topical antiparasitic for cutaneous leishmaniasis; and LIKMEZ (ATI-1501), an oral taste-masked metronidazole suspension.
Products and services
- LIKMEZ (ATI-1501): Oral, taste‑masked metronidazole suspension engineered to treat anaerobic and protozoal infections via a liquid formulation of metronidazole
- ATI-1701: Live‑attenuated vaccine candidate engineered to protect against aerosolized Francisella tularensis, targeting tularemia as a serious biothreat
- ATI-1801: Topical antiparasitic product developed to treat cutaneous leishmaniasis, addressing a disfiguring skin infection with localized application
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Appili Therapeutics
Cubist
HQ: United States
Website
- Description: Provider of biopharmaceutical products focused on the research, development, and commercialization of therapies addressing unmet medical needs in the acute care environment; markets CUBICIN (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cubist company profile →
Okogen
HQ: United States
Website
- Description: Provider of ophthalmic anti-infective drug candidates, including OKG-0303, a fixed-dose combination eyedrop for acute infectious conjunctivitis that combines an antiviral, ocular decongestant, and antibacterial; OKG-0301, an antiviral shown to inhibit viral replication in adenoviral conjunctivitis; and the RUBY trial evaluating the safety and efficacy of OKG-0301.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Okogen company profile →
Diagnostic Hybrids
HQ: United States
Website
- Description: Provider of cellular and molecular diagnostic kits and systems for detecting respiratory diseases, herpes infections, thyroid function, and other disease markers. Offers the D3 FastPoint L-DFA influenza A/B identification kit; Vitros Integrated, Chemistry, and Immunoassay Systems with broad, waterless testing menus; Ortho Vision Swift analyzer for automated donor typing; and Lyra real-time PCR assays that simplify sample processing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diagnostic Hybrids company profile →
Fluoresentric
HQ: United States
Website
- Description: Provider of assay design, optimization, and custom manufacturing services for the healthcare and biotechnology sector.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fluoresentric company profile →
Entasis Therapeutics
HQ: United States
Website
- Description: Provider of anti-infective therapies for serious drug-resistant bacterial infections. Products include GIAPREZA (angiotensin II to increase blood pressure in septic or distributive shock), XERAVA (eravacycline for complicated intra-abdominal infections), XACDURO (sulbactam/durlobactam for hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus complex), and zoliflodacin (Phase 3 for uncomplicated gonorrhea).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Entasis Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Appili Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Appili Therapeutics
2.2 - Growth funds investing in similar companies to Appili Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Appili Therapeutics
4.2 - Public trading comparable groups for Appili Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →